Armin J Bandari, MD
Cardiovascular Disease (Cardiology) · San Luis Obispo
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 24 years
- Rush Medical College of Rush University, 2002
Offices
2 locations · Pacific Central Coast Health Centers · 247 clinicians in this group
Hospitals listed: French Hospital Medical Center · Marian Regional Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Bandari’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A105051 · Current
Licensed to practise in California · since 2008 · expires 2027-09-30 · Rush Medical College of Rush University.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- French Hospital Medical CenterSan Luis Obispo, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.23, Oct 2024 – Sep 2025
- Marian Regional Medical CenterSanta Maria, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 3 of 5 · 68% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 0.67 (0.37 to 0.96), Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.081, Oct 2024 – Sep 2025
See every measure and the patient survey for French Hospital Medical Center
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.23 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.89 (0 to 1.89) · 660 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.71 (0.39 to 1.04) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 154.33 (99.56 to 209.1) · 63 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 78 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.9 · 56 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.3 · 273 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 13.7 · 355 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 275 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.5 · 69 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 1,569 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 4,085 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.07 to 0.47) · 4,358 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.69 (0.53 to 4.85) · 1,221 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.97 (0.47 to 3.48) · 567 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.54 (1.03 to 4.05) · 1,101 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.3 (0.36 to 12.23) · 585 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 3.66 (0.03 to 7.29) · 576 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.98 (0.5 to 3.47) · 185 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.2 (0 to 0.96) · 3,231 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.2 · 53 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 2.935 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.6 · 252 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 330 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -2.9 · 296 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -8.5 · 382 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 2 · 272 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 248 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.1 (3.2 to 8) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.7 (6.5 to 14.1) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 40 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10 · 77 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.7 (8.9 to 15.1) · 837 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 706 cases | No different | Jan 2024 – Dec 2024 |
What patients said (706 patients answered, 28% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 5 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 90% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 33% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 91% |
See every measure and the patient survey for Marian Regional Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 1 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 8 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.67 (0.37 to 0.96) | Better | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.081 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.99 (0.06 to 1.93) · 1,191 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 189.73 (139.29 to 240.17) · 66 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.7 · 103 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.8 · 161 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 15.9 · 247 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.7 · 478 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.4 · 470 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 237 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.5 · 3,050 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.14 (0 to 0.34) · 8,823 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.05 to 0.42) · 8,672 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.87 (0.97 to 4.76) · 2,024 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.12 (0.57 to 3.67) · 782 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.29 (0.85 to 3.72) · 1,934 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 3.63 (0 to 9.97) · 787 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.01 (1.37 to 8.65) · 748 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.88 (0.43 to 3.32) · 373 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.13 (0 to 0.73) · 6,968 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 179 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.245 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.85 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.952 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.687 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.5 · 198 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.6 · 469 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.8 · 232 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.8 · 541 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -8.6 · 473 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 434 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.6 (5 to 8.4) · 519 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.9 (8.8 to 13.4) · 519 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.2 · 152 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.3 · 83 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.2 to 17) · 124 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.9 to 1.4) · 638 cases | No different | Jan 2024 – Dec 2024 |
What patients said (666 patients answered, 17% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 64% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 79% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 68% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$381,794
Medicare paid this office $381,794 for 1,716 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 774 | $88,157 | $96 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 404 | $66,321 | $158 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 174 | $65,359 | $376 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 117 | $21,729 | $186 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 188 | $19,464 | $52 |
See all 33 services
| Return visit (30+ min) | 774 | $88,157 | $96 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 404 | $66,321 | $158 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 174 | $65,359 | $376 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 117 | $21,729 | $186 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 188 | $19,464 | $52 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 288 | $16,461 | $56 |
| New patient visit (60+ min) | 98 | $15,933 | $163 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 189 | $10,397 | $55 |
| Long return visit (40+ min) | 63 | $10,323 | $145 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 562 | $7,278 | $11 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 40 | $5,526 | $135 |
| Ultrasound of heart blood flow, valves and chambers | 116 | $5,206 | $45 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 96 | $4,372 | $20 |
| Ultrasound of both sides of head and neck blood flow | 26 | $3,929 | $146 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 49 | $3,672 | $18 |
| Injection, perflutren lipid microspheres, per ml | 51 | $3,524 | $33 |
| Injection, regadenoson, 0.1 mg | 140 | $3,276 | None |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 152 | $3,038 | $20 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $2,909 | $91 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 121 | $2,580 | $21 |
| Anticoagulant management of patient taking warfarin | 11 | $2,551 | $9 |
| Programming of dual lead pacemaker system | 62 | $1,852 | $27 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 26 | $1,606 | $25 |
| Heart rhythm recording of continous external ekg over 8-15 days | 152 | $1,602 | $11 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 17 | $946 | $56 |
| Routine electrocardiogram (ecg) using at least 12 leads with tracing | 172 | $857 | $5 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 12 | $807 | $19 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 13 | $752 | $20 |
| Programming of multiple lead implantable defibrillator system | 14 | $694 | $41 |
| Injection of x-ray contrast during ultrasound of heart | 18 | $556 | $31 |
| Programming of dual lead implantable defibrillator system | 11 | $451 | $41 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 13 | $126 | $10 |
| Injection, aminophyllin, up to 250 mg | 13 | $90 | None |
Who their Medicare patients are
1,716 Original Medicare patients in 2024. Average age 77 · Under 65 3% · 85 and older 18% · Women 45% · Also on Medicaid 10% · Health risk score 1.36. At or below the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Atrial fibrillation 42% · Coronary heart disease 38% · Chronic kidney disease 29% · Heart failure 26% · Diabetes 25% · Depression 20% · Cancer 18% · COPD 16% · Stroke 12% · Dementia 6%.
The office billed $1,450,715, Medicare allowed $513,140 and paid $381,794; for 5,929 services of 61 kinds; $6,890 of it was for drugs given in the office and $374,905 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,716 | 5,929 | 77 | 1.36 | $1,450,715 | $381,794 |
| 2023 | 1,610 | 5,882 | 77 | 1.32 | $1,134,611 | $398,669 |
| 2022 | 1,538 | 5,825 | 77 | 1.29 | $1,113,990 | $394,979 |
| 2021 | 1,701 | 6,425 | 76 | 1.33 | $1,231,313 | $449,071 |
| 2020 | 1,442 | 4,979 | 76 | 1.42 | $1,051,780 | $336,100 |
| 2019 | 1,551 | 6,220 | 76 | 1.39 | $1,285,610 | $441,996 |
| 2018 | 1,341 | 5,820 | 76 | 1.42 | $1,159,377 | $388,682 |
| 2017 | 1,349 | 6,149 | 76 | 1.42 | $1,104,117 | $394,127 |
| 2016 | 1,266 | 6,547 | 76 | 1.41 | $1,151,260 | $372,676 |
| 2015 | 1,258 | 6,515 | 76 | 1.44 | $1,077,980 | $364,843 |
| 2014 | 1,197 | 6,100 | 76 | 1.41 | $1,008,282 | $337,631 |
| 2013 | 1,140 | 5,884 | 76 | 1.42 | $959,544 | $356,765 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 34 services
| Return visit (30+ min) | 740 | $81,491 | $96 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 195 | $75,163 | $383 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 331 | $51,613 | $153 |
| Injection, regadenoson, 0.1 mg | 158 | $27,599 | None |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 194 | $21,102 | $54 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 348 | $20,125 | $56 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 102 | $18,894 | $185 |
| New patient visit (60+ min) | 95 | $16,456 | $173 |
| Long return visit (40+ min) | 72 | $11,519 | $139 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 194 | $10,339 | $53 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 638 | $8,192 | $11 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 40 | $5,420 | $136 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 65 | $4,653 | $22 |
| Ultrasound of heart blood flow, valves and chambers | 101 | $4,483 | $44 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 29 | $4,208 | $98 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 25 | $4,011 | $19 |
| Ultrasound of both sides of head and neck blood flow | 24 | $3,899 | $162 |
| Injection, perflutren lipid microspheres, per ml | 44 | $3,075 | $35 |
| Anticoagulant management of patient taking warfarin | 19 | $3,058 | $9 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 144 | $2,674 | $18 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 112 | $2,328 | $21 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 21 | $1,840 | $27 |
| Programming of dual lead pacemaker system | 49 | $1,538 | $28 |
| Heart rhythm recording of continous external ekg over 8-15 days | 137 | $1,459 | $11 |
| External shock to heart to regulate heart beat | 15 | $1,335 | $89 |
| Ultrasound of heart, follow-up | 14 | $1,130 | $71 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 18 | $841 | $47 |
| Ultrasound of heart, follow-up | 15 | $307 | $20 |
| Routine electrocardiogram (ecg) using at least 12 leads with tracing | 51 | $280 | $5 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 12 | $244 | $20 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 17 | $170 | $10 |
| Injection, aminophyllin, up to 250 mg | 17 | $118 | None |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 14 | $82 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 16 | $41 | $3 |
2022: 35 services
| Return visit (30+ min) | 764 | $85,156 | $96 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 193 | $77,263 | $398 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 292 | $43,372 | $146 |
| Injection, regadenoson, 0.1 mg | 159 | $30,879 | None |
| Long return visit (40+ min) | 130 | $21,246 | $137 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 290 | $17,623 | $58 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 193 | $17,222 | $44 |
| New patient visit (60+ min) | 72 | $11,428 | $159 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 53 | $10,612 | $200 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 193 | $10,324 | $53 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 700 | $8,446 | $11 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 51 | $8,163 | $160 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 40 | $6,589 | $84 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 71 | $4,756 | $22 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 30 | $4,496 | $21 |
| Critical care, first 30-74 minutes | 14 | $3,576 | $179 |
| Anticoagulant management of patient taking warfarin | 26 | $3,564 | $9 |
| Short return visit (20+ min) | 34 | $2,609 | $75 |
| Injection, perflutren lipid microspheres, per ml | 35 | $2,470 | $36 |
| Ultrasound of heart blood flow, valves and chambers | 52 | $2,362 | $45 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 24 | $2,130 | $27 |
| Ultrasound of both sides of head and neck blood flow | 12 | $2,062 | $172 |
| Programming of dual lead pacemaker system | 56 | $1,684 | $28 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 67 | $1,525 | $22 |
| Heart rhythm recording of continous external ekg over 8-15 days | 89 | $1,171 | $13 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 52 | $1,113 | $21 |
| Programming of dual lead implantable defibrillator system | 14 | $808 | $43 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 15 | $807 | $54 |
| Programming of multiple lead implantable defibrillator system | 11 | $723 | $48 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 13 | $546 | $17 |
| Ultrasound of heart, follow-up | 18 | $399 | $21 |
| Injection, aminophyllin, up to 250 mg | 24 | $200 | None |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 14 | $143 | $10 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 18 | $108 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 23 | $63 | $3 |
2021: 33 services
| Return visit (30+ min) | 856 | $106,465 | $99 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 168 | $70,125 | $417 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 336 | $55,968 | $162 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 160 | $27,410 | $86 |
| Injection, regadenoson, 0.1 mg | 138 | $26,263 | None |
| Long return visit (40+ min) | 142 | $23,807 | $143 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 394 | $23,691 | $59 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 61 | $12,335 | $202 |
| New patient visit (60+ min) | 64 | $11,054 | $173 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 716 | $9,815 | $12 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 167 | $8,983 | $54 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 56 | $8,589 | $86 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 50 | $8,384 | $164 |
| Anticoagulant management of patient taking warfarin | 25 | $5,480 | $9 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 75 | $5,462 | $23 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 32 | $4,728 | $21 |
| Transitional care management services for problem of high complexity | 17 | $4,137 | $230 |
| Injection, perflutren lipid microspheres, per ml | 43 | $3,550 | $38 |
| Ultrasound of heart blood flow, valves and chambers | 59 | $2,733 | $46 |
| Ultrasound of both sides of head and neck blood flow | 13 | $2,299 | $177 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 25 | $2,247 | $29 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 96 | $2,067 | $21 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 28 | $1,838 | $66 |
| Programming of dual lead pacemaker system | 54 | $1,779 | $30 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 59 | $1,319 | $22 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 21 | $1,241 | $19 |
| Heart rhythm recording of continous external ekg over 8-15 days | 81 | $1,066 | $13 |
| Programming of dual lead implantable defibrillator system | 13 | $532 | $38 |
| Ultrasound of heart, follow-up | 14 | $298 | $21 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 17 | $197 | $10 |
| Injection, aminophyllin, up to 250 mg | 22 | $157 | None |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 12 | $73 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 21 | $56 | $3 |
2020: 33 services
| Return visit (30+ min) | 696 | $72,735 | $77 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 260 | $43,098 | $163 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 99 | $41,491 | $415 |
| Long return visit (40+ min) | 198 | $24,767 | $107 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 99 | $19,537 | $98 |
| Injection, regadenoson, 0.1 mg | 80 | $15,312 | None |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 200 | $12,536 | $62 |
| New patient visit (60+ min) | 70 | $11,156 | $159 |
| Telephone medical discussion with physician, 21-30 minutes | 116 | $10,774 | $86 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 54 | $10,465 | $190 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 50 | $8,059 | $88 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 34 | $5,781 | $170 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 99 | $5,397 | $54 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 340 | $4,778 | $12 |
| Telephone medical discussion with physician, 11-20 minutes | 75 | $4,594 | $60 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 70 | $4,089 | $24 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 28 | $3,927 | $21 |
| Injection, perflutren lipid microspheres, per ml | 50 | $3,627 | $36 |
| Anticoagulant management of patient taking warfarin | 25 | $3,610 | $10 |
| Ultrasound of both sides of head and neck blood flow | 18 | $3,083 | $171 |
| Ultrasound of heart blood flow, valves and chambers | 53 | $2,431 | $46 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 27 | $2,322 | $30 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 43 | $2,212 | $14 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 86 | $1,992 | $22 |
| New patient visit (45+ min) | 11 | $1,252 | $114 |
| External ekg recording for more than 48 hours up to 21 days | 53 | $1,231 | $22 |
| Programming of dual lead pacemaker system | 41 | $1,157 | $27 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 53 | $1,155 | $22 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 15 | $1,077 | $72 |
| Ultrasound of heart, follow-up | 12 | $957 | $74 |
| Blood test, clotting time | 30 | $600 | $4 |
| Injection of x-ray contrast during ultrasound of heart | 14 | $398 | $28 |
| Injection, aminophyllin, up to 250 mg | 11 | $71 | None |
2019: 30 services
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 164 | $68,245 | $414 |
| Return visit (30+ min) | 686 | $65,282 | $81 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 344 | $57,060 | $163 |
| Long return visit (40+ min) | 316 | $44,264 | $114 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 165 | $31,824 | $96 |
| New patient visit (60+ min) | 206 | $30,618 | $149 |
| Injection, regadenoson, 0.1 mg | 121 | $21,904 | None |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 230 | $14,245 | $61 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 74 | $13,917 | $188 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 844 | $13,213 | $13 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 71 | $12,158 | $167 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 164 | $8,752 | $53 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 60 | $8,505 | $85 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 61 | $6,174 | $17 |
| Transitional care management services for problem of high complexity | 23 | $4,341 | $189 |
| Ultrasound of both sides of head and neck blood flow | 23 | $4,026 | $175 |
| Injection, perflutren lipid microspheres, per ml | 44 | $3,441 | $37 |
| Ultrasound of heart blood flow, valves and chambers | 73 | $3,378 | $46 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 48 | $3,057 | $22 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 26 | $2,923 | $20 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 27 | $2,489 | $33 |
| External shock to heart to regulate heart beat | 19 | $2,058 | $89 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 88 | $1,811 | $21 |
| External ekg recording for more than 48 hours up to 21 days | 80 | $1,810 | $23 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 73 | $1,607 | $22 |
| Programming of dual lead pacemaker system | 44 | $1,607 | $31 |
| Blood test, clotting time | 45 | $1,575 | $4 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 19 | $1,138 | $60 |
| Programming of dual lead implantable defibrillator system | 12 | $630 | $48 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 22 | $264 | $10 |
2018: 32 services
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 187 | $77,832 | $414 |
| Return visit (30+ min) | 582 | $59,503 | $77 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 279 | $47,406 | $165 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 187 | $35,636 | $95 |
| Injection, regadenoson, 0.1 mg | 128 | $22,555 | None |
| Long return visit (40+ min) | 160 | $20,978 | $108 |
| New patient visit (60+ min) | 107 | $16,553 | $155 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 203 | $11,932 | $57 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 55 | $10,557 | $192 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 650 | $9,958 | $13 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 188 | $9,851 | $52 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 43 | $8,365 | $84 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 120 | $8,189 | $16 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 38 | $6,484 | $162 |
| Transitional care management services for problem of high complexity | 18 | $3,459 | $192 |
| Ultrasound of heart, follow-up | 26 | $2,994 | $86 |
| Critical care, first 30-74 minutes | 11 | $2,862 | $179 |
| Blood test, clotting time | 115 | $2,503 | $5 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 46 | $2,482 | $22 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 21 | $2,461 | $42 |
| Ultrasound of heart blood flow, valves and chambers | 52 | $2,400 | $46 |
| Injection, perflutren lipid microspheres, per ml | 30 | $2,361 | $37 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 17 | $2,221 | $20 |
| Ultrasound of both sides of head and neck blood flow | 13 | $2,050 | $158 |
| External ekg recording for more than 48 hours up to 21 days | 60 | $1,364 | $23 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 19 | $1,350 | $71 |
| Hospital discharge day management, more than 30 minutes | 15 | $1,320 | $88 |
| Programming of dual lead pacemaker system | 39 | $1,228 | $29 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 53 | $1,173 | $22 |
| External shock to heart to regulate heart beat | 11 | $1,083 | $83 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 50 | $1,078 | $22 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 19 | $212 | $10 |
2017: 32 services
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 176 | $72,720 | $411 |
| Return visit (30+ min) | 603 | $66,252 | $78 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 296 | $54,537 | $181 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 177 | $33,931 | $95 |
| Long return visit (40+ min) | 167 | $21,164 | $105 |
| New patient visit (60+ min) | 129 | $20,013 | $155 |
| Injection, regadenoson, 0.1 mg | 113 | $19,519 | None |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 230 | $12,027 | $51 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 647 | $10,170 | $13 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 175 | $9,744 | $55 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 40 | $9,033 | $226 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 149 | $8,731 | $14 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 54 | $8,630 | $85 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 51 | $8,536 | $164 |
| Ultrasound of both sides of head and neck blood flow | 22 | $3,589 | $163 |
| Blood test, clotting time | 142 | $3,448 | $5 |
| Injection, perflutren lipid microspheres, per ml | 28 | $2,329 | $40 |
| Programming of dual lead pacemaker system | 43 | $2,208 | $42 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 39 | $2,048 | $24 |
| Transitional care management services for problem of high complexity | 11 | $1,968 | $179 |
| Ultrasound of heart blood flow, valves and chambers | 41 | $1,875 | $46 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 26 | $1,630 | $63 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 45 | $1,630 | $20 |
| External ekg recording for more than 48 hours up to 21 days | 66 | $1,472 | $22 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 66 | $1,409 | $21 |
| Ultrasound of heart, follow-up | 13 | $1,255 | $97 |
| External shock to heart to regulate heart beat | 14 | $1,251 | $83 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 12 | $1,143 | $52 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 19 | $1,042 | $20 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 41 | $892 | $22 |
| Evaluation of implantable heart and blood vessel monitoring system | 11 | $328 | $16 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 14 | $160 | $10 |
2016: 34 services
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 167 | $69,282 | $410 |
| Return visit (30+ min) | 573 | $67,121 | $76 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 243 | $45,504 | $181 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 169 | $32,276 | $95 |
| New patient visit (60+ min) | 128 | $19,750 | $154 |
| Injection, regadenoson, 0.1 mg | 84 | $14,064 | None |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 64 | $14,040 | $219 |
| Long return visit (40+ min) | 83 | $12,302 | $114 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 164 | $11,308 | $15 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 211 | $10,476 | $49 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 168 | $9,409 | $55 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 586 | $9,260 | $13 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 50 | $8,367 | $164 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 45 | $4,971 | $84 |
| Blood test, clotting time | 161 | $4,106 | $5 |
| Ultrasound of both sides of head and neck blood flow | 19 | $3,086 | $162 |
| Transitional care management services for problem of high complexity | 15 | $3,054 | $191 |
| Ultrasound of heart blood flow, valves and chambers | 58 | $2,656 | $46 |
| Programming of dual lead pacemaker system | 43 | $2,222 | $44 |
| Injection, perflutren lipid microspheres, per ml | 22 | $1,777 | $40 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 32 | $1,613 | $24 |
| External shock to heart to regulate heart beat | 16 | $1,608 | $100 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 40 | $1,529 | $19 |
| External ekg recording for more than 48 hours up to 21 days | 70 | $1,497 | $21 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 71 | $1,493 | $21 |
| Hospital discharge day management, more than 30 minutes | 16 | $1,311 | $82 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 59 | $1,285 | $22 |
| Short return visit (20+ min) | 23 | $1,277 | $56 |
| New patient visit (45+ min) | 11 | $1,267 | $115 |
| Ultrasound of heart with probe in esophagus, with report | 11 | $1,193 | $99 |
| Electrocardiogram (ecg) 2-day continuous | 23 | $454 | $20 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 23 | $438 | $19 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 14 | $366 | None |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 16 | $45 | $3 |
2015: 34 services
| Return visit (30+ min) | 509 | $66,293 | $77 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 153 | $62,864 | $408 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 214 | $40,571 | $181 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 153 | $40,217 | $131 |
| New patient visit (60+ min) | 120 | $18,858 | $157 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 60 | $13,251 | $221 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 174 | $12,470 | $15 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 235 | $12,242 | $51 |
| Injection, regadenoson, 0.1 mg | 66 | $11,097 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 59 | $10,137 | $164 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 154 | $8,569 | $55 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 52 | $8,380 | $84 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 475 | $7,749 | $13 |
| Ultrasound of both sides of head and neck blood flow | 37 | $6,341 | $171 |
| Long return visit (40+ min) | 48 | $6,182 | $117 |
| Blood test, clotting time | 173 | $4,514 | $5 |
| Ultrasound of heart blood flow, valves and chambers | 61 | $2,808 | $46 |
| Short return visit (20+ min) | 39 | $2,502 | $60 |
| Programming of dual lead pacemaker system | 46 | $2,379 | $43 |
| Ultrasound of heart, follow-up | 12 | $1,796 | $106 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 45 | $1,553 | $23 |
| External shock to heart to regulate heart beat | 14 | $1,511 | $101 |
| External ekg recording for more than 48 hours up to 21 days | 65 | $1,478 | $22 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 52 | $1,441 | $18 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 61 | $1,353 | $22 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 59 | $1,308 | $21 |
| Injection, perflutren lipid microspheres, per ml | 14 | $1,129 | $42 |
| Hospital discharge day management, more than 30 minutes | 11 | $966 | $88 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 14 | $672 | $21 |
| Electrocardiogram (ecg) 2-day continuous | 26 | $552 | $21 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 26 | $547 | $21 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 16 | $526 | None |
| Ultrasound of heart, follow-up | 11 | $233 | $19 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 14 | $45 | $3 |
2014: 29 services
| Return visit (30+ min) | 546 | $68,446 | $75 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 130 | $52,522 | $404 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 130 | $33,668 | $129 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 179 | $33,025 | $177 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 266 | $14,115 | $52 |
| New patient visit (60+ min) | 92 | $13,878 | $151 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 159 | $12,573 | $15 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 56 | $12,144 | $217 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 69 | $11,387 | $163 |
| Long return visit (40+ min) | 71 | $10,675 | $110 |
| Injection, regadenoson, 0.1 mg | 65 | $10,669 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 58 | $8,888 | $84 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 464 | $7,834 | $13 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 130 | $7,088 | $55 |
| Blood test, clotting time | 150 | $4,525 | $5 |
| Ultrasound of both sides of head and neck blood flow | 27 | $4,334 | $161 |
| Ultrasound of heart blood flow, valves and chambers | 56 | $2,513 | $45 |
| Ultrasound of heart, follow-up | 20 | $2,390 | $100 |
| Programming of dual lead pacemaker system | 34 | $1,715 | $40 |
| Short return visit (20+ min) | 27 | $1,489 | $53 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 26 | $1,366 | $24 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 63 | $1,279 | $20 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 56 | $1,213 | $22 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 33 | $1,200 | $18 |
| External ekg recording for more than 48 hours up to 21 days | 63 | $925 | $14 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 20 | $410 | $21 |
| Electrocardiogram (ecg) 2-day continuous | 20 | $409 | $20 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 11 | $83 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 15 | $45 | $3 |
2013: 33 services
| Return visit (30+ min) | 513 | $79,756 | $78 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 129 | $54,578 | $417 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 129 | $34,060 | $130 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 183 | $28,848 | $153 |
| New patient visit (60+ min) | 122 | $18,297 | $150 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 103 | $16,834 | $157 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 314 | $15,646 | $49 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 116 | $12,593 | $15 |
| Long return visit (40+ min) | 86 | $11,845 | $111 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 76 | $11,744 | $82 |
| Injection, regadenoson, 0.1 mg | 56 | $9,634 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 494 | $9,076 | $14 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 129 | $7,398 | $56 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 38 | $6,840 | $180 |
| Blood test, clotting time | 114 | $4,634 | $5 |
| Critical care, first 30-74 minutes | 18 | $3,838 | $174 |
| Ultrasound of both sides of head and neck blood flow | 23 | $3,496 | $152 |
| Hospital discharge day management, more than 30 minutes | 40 | $3,399 | $83 |
| Programming of dual lead pacemaker system | 38 | $2,192 | $41 |
| Injection, adenosine for diagnostic use, 30 mg (not to be used to report any adenosine phosphate compounds; instead use a9270) | 12 | $2,072 | None |
| External shock to heart to regulate heart beat | 17 | $1,790 | $94 |
| Ultrasound of heart, follow-up | 17 | $1,609 | $85 |
| Ultrasound of heart blood flow, valves and chambers | 38 | $1,425 | $38 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 23 | $1,068 | $23 |
| Short return visit (20+ min) | 23 | $1,055 | $46 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 26 | $955 | $19 |
| Electrocardiogram (ecg) 2-day continuous | 34 | $805 | $24 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 34 | $720 | $21 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 38 | $637 | $17 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 24 | $484 | $20 |
| External ekg recording for more than 48 hours up to 21 days | 24 | $247 | $10 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 26 | $178 | $7 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 12 | $35 | $3 |
Medicaid work
$1,772 in 2024
Medicaid paid $1,772 for 14 billed services this clinician did in 2024, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 14 | $1,772 |
| 2024 | 14 | 1 | 13 | $1,772 |
| 2023 | 101 | 2 | 22 | $4,734 |
| 2022 | 52 | 1 | 15 | $3,309 |
| 2021 | 231 | 3 | 26 | $18,727 |
| 2020 | 28 | 2 | 15 | $2,074 |
| 2019 | 62 | 3 | 13 | $6,499 |
| 2018 | 24 | 1 | 12 | $2,373 |
See the largest Medicaid services in earlier years
2023
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 89 | $4,633 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 12 | $101 |
2022
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 52 | $3,309 |
2021
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 179 | $13,638 |
| Return visit (30+ min) | 33 | $4,874 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 19 | $215 |
2020
| Return visit (30+ min) | 15 | $1,877 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 13 | $197 |
2019
| Return visit (30+ min) | 25 | $3,221 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 24 | $3,059 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 13 | $219 |
2018
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 24 | $2,373 |
Drugs they prescribed that Part D paid
$1,173,344
Pharmacies billed $1,173,344 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 4,251) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
3,391 generic and 860 brand-name prescriptions · $1,173,344 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 459 | $638,081 | $1,390 |
| Xarelto | 141 | $191,606 | $1,359 |
| Entresto | 78 | $115,205 | $1,477 |
| Repatha Sureclick | 63 | $59,679 | $947 |
| Farxiga | 48 | $54,858 | $1,143 |
See all 46 drugs
| Eliquis | 459 | $638,081 | $1,390 |
| Xarelto | 141 | $191,606 | $1,359 |
| Entresto | 78 | $115,205 | $1,477 |
| Repatha Sureclick | 63 | $59,679 | $947 |
| Farxiga | 48 | $54,858 | $1,143 |
| Praluent | 14 | $20,298 | $1,450 |
| Metoprolol | 751 | $14,347 | $19 |
| Valsartan | 231 | $7,661 | $33 |
| Atorvastatin | 339 | $4,958 | $15 |
| Valsartan-Hydrochlorothiazide | 74 | $4,576 | $62 |
| Rosuvastatin | 245 | $4,292 | $18 |
| Diltiazem 24hr Er (Cd) | 83 | $4,185 | $50 |
| Flecainide Acetate | 67 | $2,994 | $45 |
| Carvedilol | 207 | $2,284 | $11 |
| Amlodipine Besylate | 235 | $1,894 | $8 |
| Labetalol | 50 | $1,664 | $33 |
| Losartan | 124 | $1,446 | $12 |
| Eplerenone | 15 | $1,157 | $77 |
| Spironolactone | 133 | $1,127 | $8 |
| Ezetimibe | 32 | $1,057 | $33 |
| Ranolazine Er | 14 | $1,041 | $74 |
| Potassium Chloride | 38 | $1,023 | $27 |
| Losartan-Hydrochlorothiazide | 33 | $993 | $30 |
| Isosorbide Mononitrate Er | 62 | $960 | $15 |
| Furosemide | 95 | $904 | $10 |
| Nebivolol | 11 | $839 | $76 |
| Olmesartan Medoxomil | 47 | $788 | $17 |
| Propafenone | 11 | $737 | $67 |
| Diltiazem 24hr Er | 16 | $713 | $45 |
| Diltiazem 24hr Er (Xr) | 19 | $711 | $37 |
| Olmesartan-Hydrochlorothiazide | 13 | $588 | $45 |
| Torsemide | 28 | $578 | $21 |
| Clopidogrel | 42 | $563 | $13 |
| Lisinopril | 78 | $490 | $6 |
| Fenofibrate | 12 | $410 | $34 |
| Amiodarone | 26 | $408 | $16 |
| Irbesartan | 23 | $407 | $18 |
| Sotalol | 15 | $345 | $23 |
| Warfarin | 20 | $342 | $17 |
| Pravastatin | 15 | $283 | $19 |
| Digoxin | 12 | $261 | $22 |
| Metoprolol | 24 | $172 | $7 |
| Ramipril | 12 | $148 | $12 |
| Nitroglycerin | 11 | $114 | $10 |
| Simvastatin | 18 | $78 | $4 |
| Hydrochlorothiazide | 23 | $46 | $2 |
Year by year
| 2024 | 4,251 | 624 | 0% (0) | 20% | $1,173,344 |
| 2023 | 4,600 | 649 | 0% (0) | 22% | $1,296,257 |
| 2022 | 5,046 | 695 | 0% (0) | 19% | $1,250,805 |
| 2021 | 4,995 | 699 | 0% (0) | 19% | $1,131,001 |
| 2020 | 4,827 | 637 | 0% (0) | 21% | $1,002,299 |
| 2019 | 4,800 | 637 | 0% (0) | 21% | $864,559 |
| 2018 | 4,689 | 591 | None | 20% | $725,094 |
| 2017 | 4,667 | 584 | 0% (0) | 24% | $551,577 |
| 2016 | 4,832 | 550 | 0% (0) | 26% | $509,147 |
| 2015 | 4,535 | 483 | 0% (0) | 28% | $414,126 |
| 2014 | 4,684 | 455 | None | None | $394,618 |
| 2013 | 4,150 | 418 | None | 31% | $291,470 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 46 drugs
| Eliquis | 555 | $711,052 | $1,281 |
| Xarelto | 182 | $246,837 | $1,356 |
| Entresto | 56 | $85,434 | $1,526 |
| Repatha Sureclick | 96 | $74,382 | $775 |
| Farxiga | 20 | $26,447 | $1,322 |
| Metoprolol | 775 | $20,907 | $27 |
| Praluent | 14 | $20,745 | $1,482 |
| Valsartan | 212 | $9,706 | $46 |
| Rosuvastatin | 267 | $8,412 | $32 |
| Diltiazem 24hr Er (Cd) | 100 | $7,674 | $77 |
| Atorvastatin | 352 | $6,652 | $19 |
| Valsartan-Hydrochlorothiazide | 73 | $5,684 | $78 |
| Nebivolol | 17 | $4,182 | $246 |
| Labetalol | 68 | $4,153 | $61 |
| Amlodipine Besylate | 274 | $4,076 | $15 |
| Olmesartan Medoxomil | 51 | $3,419 | $67 |
| Carvedilol | 215 | $2,993 | $14 |
| Losartan | 154 | $2,833 | $18 |
| Flecainide Acetate | 50 | $2,595 | $52 |
| Ezetimibe | 31 | $1,644 | $53 |
| Spironolactone | 127 | $1,547 | $12 |
| Eplerenone | 15 | $1,430 | $95 |
| Amlodipine Besylate-Benazepril | 23 | $1,368 | $59 |
| Furosemide | 112 | $1,266 | $11 |
| Amiodarone | 39 | $1,231 | $32 |
| Torsemide | 39 | $1,158 | $30 |
| Enoxaparin | 11 | $1,095 | $100 |
| Potassium Chloride | 30 | $1,052 | $35 |
| Lisinopril | 87 | $1,017 | $12 |
| Losartan-Hydrochlorothiazide | 31 | $943 | $30 |
| Amlodipine-Valsartan | 11 | $941 | $86 |
| Isosorbide Mononitrate Er | 42 | $836 | $20 |
| Clopidogrel | 53 | $805 | $15 |
| Olmesartan-Hydrochlorothiazide | 20 | $639 | $32 |
| Diltiazem 24hr Er | 28 | $623 | $22 |
| Hydralazine | 15 | $457 | $30 |
| Digoxin | 17 | $401 | $24 |
| Irbesartan | 25 | $341 | $14 |
| Sotalol | 24 | $308 | $13 |
| Ramipril | 17 | $293 | $17 |
| Diltiazem 24hr Er (Xr) | 11 | $279 | $25 |
| Warfarin | 14 | $209 | $15 |
| Hydrochlorothiazide | 32 | $148 | $5 |
| Metoprolol | 17 | $129 | $8 |
| Pravastatin | 11 | $96 | $9 |
| Simvastatin | 14 | $55 | $4 |
2022: 50 drugs
| Eliquis | 541 | $651,565 | $1,204 |
| Xarelto | 193 | $263,428 | $1,365 |
| Entresto | 66 | $77,534 | $1,175 |
| Repatha Sureclick | 84 | $64,950 | $773 |
| Praluent | 19 | $23,960 | $1,261 |
| Metoprolol | 837 | $22,388 | $27 |
| Pradaxa | 15 | $21,922 | $1,461 |
| Farxiga | 14 | $12,989 | $928 |
| Valsartan | 234 | $12,499 | $53 |
| Rosuvastatin | 273 | $9,270 | $34 |
| Diltiazem 24hr Er (Cd) | 103 | $8,685 | $84 |
| Atorvastatin | 426 | $6,840 | $16 |
| Valsartan-Hydrochlorothiazide | 90 | $6,170 | $69 |
| Flecainide Acetate | 52 | $4,312 | $83 |
| Olmesartan Medoxomil | 76 | $3,824 | $50 |
| Labetalol | 60 | $3,540 | $59 |
| Carvedilol | 237 | $3,222 | $14 |
| Losartan | 159 | $3,204 | $20 |
| Eplerenone | 21 | $3,160 | $150 |
| Amlodipine Besylate | 306 | $2,707 | $9 |
| Nebivolol | 18 | $2,634 | $146 |
| Digoxin | 36 | $1,665 | $46 |
| Spironolactone | 135 | $1,506 | $11 |
| Ezetimibe | 35 | $1,470 | $42 |
| Olmesartan-Hydrochlorothiazide | 22 | $1,424 | $65 |
| Losartan-Hydrochlorothiazide | 39 | $1,212 | $31 |
| Fenofibrate | 14 | $1,209 | $86 |
| Torsemide | 42 | $1,188 | $28 |
| Clopidogrel | 58 | $1,178 | $20 |
| Amlodipine Besylate-Benazepril | 24 | $1,142 | $48 |
| Furosemide | 143 | $1,135 | $8 |
| Amlodipine-Valsartan | 13 | $1,120 | $86 |
| Potassium Chloride | 31 | $917 | $30 |
| Isosorbide Mononitrate Er | 41 | $895 | $22 |
| Diltiazem 24hr Er | 18 | $879 | $49 |
| Lisinopril | 107 | $852 | $8 |
| Nifedipine Er | 11 | $776 | $71 |
| Dilt-Xr | 17 | $747 | $44 |
| Amiodarone | 24 | $620 | $26 |
| Warfarin | 23 | $542 | $24 |
| Sotalol | 24 | $497 | $21 |
| Nitroglycerin | 22 | $345 | $16 |
| Pravastatin | 18 | $322 | $18 |
| Hydralazine | 13 | $312 | $24 |
| Hydrochlorothiazide | 49 | $284 | $6 |
| Ramipril | 17 | $263 | $15 |
| Atenolol | 16 | $219 | $14 |
| Metoprolol | 28 | $216 | $8 |
| Simvastatin | 20 | $190 | $9 |
| Lisinopril-Hydrochlorothiazide | 15 | $128 | $9 |
2021: 51 drugs
| Eliquis | 517 | $599,355 | $1,159 |
| Xarelto | 223 | $275,381 | $1,235 |
| Repatha Sureclick | 70 | $48,690 | $696 |
| Entresto | 35 | $37,293 | $1,066 |
| Praluent | 36 | $22,450 | $624 |
| Metoprolol | 804 | $20,940 | $26 |
| Pradaxa | 13 | $16,519 | $1,271 |
| Valsartan | 175 | $12,408 | $71 |
| Diltiazem 24hr Er (Cd) | 100 | $8,596 | $86 |
| Rosuvastatin | 266 | $7,886 | $30 |
| Atorvastatin | 407 | $6,842 | $17 |
| Bystolic | 17 | $6,595 | $388 |
| Valsartan-Hydrochlorothiazide | 102 | $6,201 | $61 |
| Olmesartan Medoxomil | 74 | $5,221 | $71 |
| Losartan | 197 | $4,378 | $22 |
| Flecainide Acetate | 55 | $4,259 | $77 |
| Labetalol | 60 | $3,730 | $62 |
| Dilt-Xr | 41 | $3,367 | $82 |
| Amlodipine Besylate | 327 | $2,689 | $8 |
| Carvedilol | 217 | $2,639 | $12 |
| Digoxin | 47 | $2,413 | $51 |
| Eplerenone | 18 | $2,399 | $133 |
| Spironolactone | 126 | $1,446 | $11 |
| Potassium Chloride | 43 | $1,406 | $33 |
| Fenofibrate | 19 | $1,342 | $71 |
| Ezetimibe | 33 | $1,211 | $37 |
| Olmesartan-Hydrochlorothiazide | 20 | $1,158 | $58 |
| Torsemide | 43 | $1,134 | $26 |
| Clopidogrel | 72 | $1,102 | $15 |
| Lisinopril | 129 | $1,097 | $9 |
| Furosemide | 143 | $1,053 | $7 |
| Ranolazine Er | 11 | $1,037 | $94 |
| Amlodipine-Valsartan | 12 | $1,013 | $84 |
| Losartan-Hydrochlorothiazide | 34 | $969 | $29 |
| Diltiazem 24hr Er | 16 | $870 | $54 |
| Warfarin | 32 | $861 | $27 |
| Amlodipine Besylate-Benazepril | 24 | $830 | $35 |
| Amiodarone | 24 | $816 | $34 |
| Isosorbide Mononitrate Er | 35 | $619 | $18 |
| Nitroglycerin | 27 | $560 | $21 |
| Cartia Xt | 14 | $552 | $39 |
| Hydralazine | 18 | $488 | $27 |
| Sotalol | 25 | $468 | $19 |
| Chlorthalidone | 11 | $386 | $35 |
| Irbesartan | 18 | $354 | $20 |
| Metoprolol | 28 | $312 | $11 |
| Pravastatin | 24 | $307 | $13 |
| Hydrochlorothiazide | 33 | $233 | $7 |
| Ramipril | 11 | $193 | $18 |
| Lisinopril-Hydrochlorothiazide | 11 | $148 | $13 |
| Simvastatin | 20 | $100 | $5 |
2020: 50 drugs
| Eliquis | 501 | $506,505 | $1,011 |
| Xarelto | 251 | $265,487 | $1,058 |
| Repatha Sureclick | 47 | $27,941 | $594 |
| Entresto | 26 | $26,797 | $1,031 |
| Metoprolol | 705 | $22,067 | $31 |
| Praluent | 16 | $15,865 | $992 |
| Rosuvastatin | 248 | $11,751 | $47 |
| Pradaxa | 14 | $11,677 | $834 |
| Valsartan | 153 | $11,660 | $76 |
| Diltiazem 24hr Er (Cd) | 89 | $10,409 | $117 |
| Atorvastatin | 422 | $8,406 | $20 |
| Brilinta | 14 | $6,073 | $434 |
| Valsartan-Hydrochlorothiazide | 87 | $5,688 | $65 |
| Bystolic | 13 | $4,644 | $357 |
| Losartan | 212 | $4,029 | $19 |
| Labetalol | 60 | $3,740 | $62 |
| Olmesartan Medoxomil | 68 | $3,621 | $53 |
| Ranolazine Er | 21 | $3,548 | $169 |
| Eplerenone | 18 | $3,370 | $187 |
| Flecainide Acetate | 25 | $3,280 | $131 |
| Dilt-Xr | 23 | $2,725 | $118 |
| Carvedilol | 257 | $2,709 | $11 |
| Amlodipine Besylate | 305 | $2,437 | $8 |
| Lisinopril | 159 | $1,637 | $10 |
| Midodrine | 11 | $1,619 | $147 |
| Olmesartan-Hydrochlorothiazide | 28 | $1,608 | $57 |
| Digoxin | 34 | $1,481 | $44 |
| Spironolactone | 121 | $1,464 | $12 |
| Potassium Chloride | 54 | $1,411 | $26 |
| Amlodipine-Valsartan | 14 | $1,297 | $93 |
| Irbesartan | 23 | $1,284 | $56 |
| Clopidogrel | 76 | $1,108 | $15 |
| Diltiazem 24hr Er | 21 | $1,057 | $50 |
| Ezetimibe | 16 | $1,032 | $65 |
| Cartia Xt | 23 | $1,003 | $44 |
| Furosemide | 148 | $1,002 | $7 |
| Torsemide | 45 | $988 | $22 |
| Warfarin | 49 | $979 | $20 |
| Amlodipine Besylate-Benazepril | 26 | $886 | $34 |
| Sotalol | 25 | $706 | $28 |
| Losartan-Hydrochlorothiazide | 28 | $608 | $22 |
| Nitroglycerin | 13 | $554 | $43 |
| Isosorbide Mononitrate Er | 26 | $452 | $17 |
| Cilostazol | 11 | $436 | $40 |
| Amiodarone | 13 | $416 | $32 |
| Pravastatin | 23 | $414 | $18 |
| Hydrochlorothiazide | 47 | $268 | $6 |
| Lisinopril-Hydrochlorothiazide | 13 | $189 | $15 |
| Metoprolol | 20 | $146 | $7 |
| Simvastatin | 16 | $58 | $4 |
2019: 52 drugs
| Eliquis | 450 | $397,371 | $883 |
| Xarelto | 254 | $231,886 | $913 |
| Metoprolol | 708 | $28,101 | $40 |
| Repatha Sureclick | 21 | $21,698 | $1,033 |
| Praluent | 19 | $16,086 | $847 |
| Rosuvastatin | 246 | $15,325 | $62 |
| Diltiazem 24hr Er (Cd) | 77 | $10,610 | $138 |
| Atorvastatin | 431 | $10,186 | $24 |
| Entresto | 17 | $9,738 | $573 |
| Valsartan | 111 | $7,489 | $67 |
| Ranolazine Er | 20 | $6,864 | $343 |
| Olmesartan Medoxomil | 92 | $6,764 | $74 |
| Brilinta | 12 | $6,704 | $559 |
| Bystolic | 19 | $5,426 | $286 |
| Eplerenone | 25 | $4,538 | $182 |
| Flecainide Acetate | 42 | $4,061 | $97 |
| Potassium Chloride | 65 | $4,020 | $62 |
| Labetalol | 54 | $3,769 | $70 |
| Carvedilol | 290 | $3,722 | $13 |
| Valsartan-Hydrochlorothiazide | 68 | $3,128 | $46 |
| Losartan | 193 | $2,479 | $13 |
| Dilt-Xr | 25 | $2,357 | $94 |
| Amlodipine Besylate | 258 | $2,343 | $9 |
| Cartia Xt | 47 | $2,270 | $48 |
| Diltiazem 24hr Er | 22 | $1,890 | $86 |
| Spironolactone | 122 | $1,685 | $14 |
| Lisinopril | 178 | $1,655 | $9 |
| Toprol Xl | 29 | $1,618 | $56 |
| Warfarin | 68 | $1,410 | $21 |
| Digoxin | 34 | $1,396 | $41 |
| Amlodipine-Valsartan | 18 | $1,302 | $72 |
| Amiodarone | 16 | $1,214 | $76 |
| Torsemide | 59 | $1,206 | $20 |
| Furosemide | 176 | $1,191 | $7 |
| Olmesartan-Hydrochlorothiazide | 17 | $1,012 | $60 |
| Clopidogrel | 73 | $957 | $13 |
| Ezetimibe | 11 | $911 | $83 |
| Amlodipine Besylate-Benazepril | 13 | $903 | $69 |
| Irbesartan | 18 | $854 | $47 |
| Telmisartan | 12 | $786 | $66 |
| Sotalol | 19 | $772 | $41 |
| Losartan-Hydrochlorothiazide | 40 | $635 | $16 |
| Pravastatin | 30 | $571 | $19 |
| Pantoprazole | 16 | $287 | $18 |
| Isosorbide Mononitrate Er | 16 | $281 | $18 |
| Lisinopril-Hydrochlorothiazide | 11 | $185 | $17 |
| Benazepril | 13 | $152 | $12 |
| Ramipril | 11 | $120 | $11 |
| Hydrochlorothiazide | 27 | $120 | $4 |
| Simvastatin | 15 | $120 | $8 |
| Metoprolol | 14 | $51 | $4 |
| Cilostazol | 13 | $40 | $3 |
2018: 46 drugs
| Eliquis | 362 | $278,240 | $769 |
| Xarelto | 256 | $199,125 | $778 |
| Metoprolol | 677 | $30,226 | $45 |
| Repatha Sureclick | 19 | $29,484 | $1,552 |
| Praluent | 21 | $25,674 | $1,223 |
| Pradaxa | 28 | $18,971 | $678 |
| Atorvastatin | 424 | $10,293 | $24 |
| Rosuvastatin | 216 | $9,872 | $46 |
| Diltiazem 24hr Er (Cd) | 71 | $7,437 | $105 |
| Olmesartan Medoxomil | 97 | $6,456 | $67 |
| Potassium Chloride | 67 | $5,837 | $87 |
| Valsartan | 145 | $5,786 | $40 |
| Eplerenone | 27 | $4,816 | $178 |
| Flecainide Acetate | 43 | $4,516 | $105 |
| Labetalol | 65 | $3,624 | $56 |
| Valsartan-Hydrochlorothiazide | 86 | $3,337 | $39 |
| Carvedilol | 296 | $3,031 | $10 |
| Warfarin | 125 | $2,632 | $21 |
| Coumadin | 12 | $2,331 | $194 |
| Cartia Xt | 47 | $2,298 | $49 |
| Amlodipine Besylate | 232 | $2,115 | $9 |
| Amlodipine-Valsartan | 22 | $1,839 | $84 |
| Losartan | 141 | $1,721 | $12 |
| Torsemide | 71 | $1,688 | $24 |
| Spironolactone | 121 | $1,612 | $13 |
| Olmesartan-Hydrochlorothiazide | 19 | $1,596 | $84 |
| Digoxin | 23 | $1,517 | $66 |
| Ezetimibe | 14 | $1,492 | $107 |
| Lisinopril | 192 | $1,416 | $7 |
| Amlodipine Besylate-Benazepril | 12 | $1,098 | $92 |
| Clopidogrel | 70 | $1,098 | $16 |
| Diltiazem 24hr Er | 12 | $1,084 | $90 |
| Toprol Xl | 16 | $933 | $58 |
| Losartan-Hydrochlorothiazide | 48 | $919 | $19 |
| Furosemide | 148 | $799 | $5 |
| Telmisartan | 11 | $775 | $70 |
| Isosorbide Mononitrate Er | 21 | $574 | $27 |
| Irbesartan | 13 | $559 | $43 |
| Amiodarone | 19 | $559 | $29 |
| Sotalol | 12 | $429 | $36 |
| Pravastatin | 25 | $389 | $16 |
| Pantoprazole | 35 | $346 | $10 |
| Hydrochlorothiazide | 31 | $185 | $6 |
| Simvastatin | 24 | $175 | $7 |
| Lisinopril-Hydrochlorothiazide | 20 | $172 | $9 |
| Hydralazine | 14 | $94 | $7 |
2017: 45 drugs
| Eliquis | 262 | $183,036 | $699 |
| Xarelto | 260 | $161,804 | $622 |
| Metoprolol | 636 | $25,664 | $40 |
| Repatha Sureclick | 21 | $24,798 | $1,181 |
| Pradaxa | 22 | $17,330 | $788 |
| Atorvastatin | 484 | $11,056 | $23 |
| Rosuvastatin | 185 | $8,889 | $48 |
| Ranexa | 15 | $7,691 | $513 |
| Valsartan | 210 | $7,118 | $34 |
| Diltiazem 24hr Cd | 13 | $5,814 | $447 |
| Flecainide Acetate | 58 | $4,967 | $86 |
| Diltiazem 24hr Er | 63 | $4,462 | $71 |
| Potassium Chloride | 72 | $4,462 | $62 |
| Crestor | 12 | $4,279 | $357 |
| Valsartan-Hydrochlorothiazide | 90 | $3,720 | $41 |
| Labetalol | 54 | $3,633 | $67 |
| Eplerenone | 21 | $3,373 | $161 |
| Dofetilide | 12 | $2,947 | $246 |
| Carvedilol | 251 | $2,673 | $11 |
| Warfarin | 154 | $2,656 | $17 |
| Coumadin | 13 | $2,258 | $174 |
| Digoxin | 44 | $2,247 | $51 |
| Cartia Xt | 52 | $2,096 | $40 |
| Amlodipine Besylate | 244 | $1,875 | $8 |
| Amlodipine-Valsartan | 25 | $1,865 | $75 |
| Spironolactone | 152 | $1,814 | $12 |
| Fenofibrate | 18 | $1,763 | $98 |
| Lisinopril | 224 | $1,506 | $7 |
| Clopidogrel | 85 | $1,451 | $17 |
| Losartan | 122 | $1,269 | $10 |
| Isosorbide Mononitrate Er | 39 | $1,179 | $30 |
| Amiodarone | 51 | $1,115 | $22 |
| Torsemide | 35 | $1,111 | $32 |
| Digox | 13 | $1,104 | $85 |
| Losartan-Hydrochlorothiazide | 58 | $986 | $17 |
| Telmisartan | 15 | $916 | $61 |
| Furosemide | 159 | $814 | $5 |
| Pantoprazole | 46 | $607 | $13 |
| Pravastatin | 23 | $316 | $14 |
| Simvastatin | 34 | $253 | $7 |
| Lisinopril-Hydrochlorothiazide | 23 | $239 | $10 |
| Hydrochlorothiazide | 28 | $190 | $7 |
| Lovastatin | 14 | $164 | $12 |
| Triamterene-Hydrochlorothiazid | 11 | $153 | $14 |
| Atenolol | 17 | $138 | $8 |
2016: 51 drugs
| Xarelto | 255 | $147,594 | $579 |
| Eliquis | 168 | $96,234 | $573 |
| Crestor | 122 | $46,727 | $383 |
| Pradaxa | 48 | $33,918 | $707 |
| Metoprolol | 653 | $23,306 | $36 |
| Repatha Sureclick | 12 | $22,233 | $1,853 |
| Diltiazem 24hr Er | 90 | $16,307 | $181 |
| Valsartan | 177 | $13,627 | $77 |
| Atorvastatin | 490 | $12,460 | $25 |
| Rosuvastatin | 68 | $8,623 | $127 |
| Zetia | 19 | $6,701 | $353 |
| Ranexa | 18 | $5,769 | $321 |
| Potassium Chloride | 100 | $5,193 | $52 |
| Valsartan-Hydrochlorothiazide | 130 | $4,485 | $35 |
| Effient | 11 | $4,192 | $381 |
| Labetalol | 68 | $4,054 | $60 |
| Eplerenone | 29 | $4,027 | $139 |
| Carvedilol | 270 | $2,833 | $10 |
| Flecainide Acetate | 53 | $2,630 | $50 |
| Warfarin | 175 | $2,579 | $15 |
| Amlodipine-Valsartan | 26 | $2,391 | $92 |
| Digoxin | 47 | $2,173 | $46 |
| Amlodipine Besylate | 260 | $2,123 | $8 |
| Spironolactone | 165 | $1,852 | $11 |
| Fenofibrate | 19 | $1,699 | $89 |
| Losartan | 134 | $1,658 | $12 |
| Lisinopril | 209 | $1,628 | $8 |
| Torsemide | 63 | $1,534 | $24 |
| Clopidogrel | 85 | $1,423 | $17 |
| Amiodarone | 67 | $1,317 | $20 |
| Cartia Xt | 30 | $1,266 | $42 |
| Bumetanide | 12 | $1,265 | $105 |
| Amlodipine Besylate-Benazepril | 16 | $1,265 | $79 |
| Enoxaparin | 12 | $1,160 | $97 |
| Telmisartan | 15 | $1,156 | $77 |
| Nitrostat | 15 | $932 | $62 |
| Toprol Xl | 13 | $877 | $67 |
| Furosemide | 156 | $802 | $5 |
| Pantoprazole | 49 | $743 | $15 |
| Losartan-Hydrochlorothiazide | 54 | $719 | $13 |
| Simvastatin | 72 | $618 | $9 |
| Isosorbide Mononitrate Er | 23 | $492 | $21 |
| Spironolactone-Hctz | 12 | $448 | $37 |
| Diltiazem 24hr Cd | 14 | $447 | $32 |
| Pravastatin | 17 | $361 | $21 |
| Hydrochlorothiazide | 36 | $254 | $7 |
| Triamterene-Hydrochlorothiazid | 19 | $220 | $12 |
| Klor-Con 10 | 12 | $172 | $14 |
| Lovastatin | 11 | $161 | $15 |
| Atenolol | 28 | $157 | $6 |
| Lisinopril-Hydrochlorothiazide | 18 | $97 | $5 |
2015: 47 drugs
| Xarelto | 215 | $102,530 | $477 |
| Crestor | 191 | $63,685 | $333 |
| Eliquis | 125 | $60,759 | $486 |
| Pradaxa | 52 | $33,101 | $637 |
| Metoprolol | 670 | $25,936 | $39 |
| Diltiazem 24hr Er | 92 | $14,966 | $163 |
| Atorvastatin | 418 | $11,984 | $29 |
| Valsartan | 82 | $11,115 | $136 |
| Zetia | 38 | $8,830 | $232 |
| Ranexa | 16 | $5,019 | $314 |
| Potassium Chloride | 133 | $4,914 | $37 |
| Labetalol | 103 | $4,757 | $46 |
| Valsartan-Hydrochlorothiazide | 115 | $4,454 | $39 |
| Fenofibrate | 16 | $3,116 | $195 |
| Eplerenone | 18 | $2,920 | $162 |
| Diovan | 13 | $2,911 | $224 |
| Telmisartan | 13 | $2,784 | $214 |
| Flecainide Acetate | 30 | $2,547 | $85 |
| Amlodipine Besylate | 300 | $2,539 | $8 |
| Warfarin | 132 | $2,351 | $18 |
| Carvedilol | 244 | $2,248 | $9 |
| Diltiazem 24hr Cd | 22 | $2,205 | $100 |
| Digoxin | 46 | $2,164 | $47 |
| Amiodarone | 61 | $1,799 | $29 |
| Amlodipine-Valsartan | 13 | $1,758 | $135 |
| Lisinopril | 235 | $1,624 | $7 |
| Losartan | 149 | $1,530 | $10 |
| Amlodipine Besylate-Benazepril | 23 | $1,430 | $62 |
| Torsemide | 59 | $1,308 | $22 |
| Spironolactone | 124 | $1,056 | $9 |
| Cartia Xt | 21 | $1,044 | $50 |
| Clopidogrel | 76 | $1,028 | $14 |
| Diltiazem Er | 14 | $949 | $68 |
| Furosemide | 159 | $884 | $6 |
| Toprol Xl | 12 | $789 | $66 |
| Simvastatin | 66 | $644 | $10 |
| Fenofibrate | 16 | $642 | $40 |
| Losartan-Hydrochlorothiazide | 46 | $642 | $14 |
| Pantoprazole | 39 | $631 | $16 |
| Pravastatin | 15 | $568 | $38 |
| Isosorbide Mononitrate Er | 20 | $466 | $23 |
| Nitrostat | 16 | $436 | $27 |
| Triamterene-Hydrochlorothiazid | 22 | $277 | $13 |
| Hydrochlorothiazide | 27 | $201 | $7 |
| Atenolol | 18 | $136 | $8 |
| Metoprolol | 12 | $130 | $11 |
| Ramipril | 16 | $120 | $8 |
2014: 50 drugs
| Xarelto | 200 | $81,162 | $406 |
| Crestor | 200 | $63,382 | $317 |
| Pradaxa | 75 | $39,816 | $531 |
| Metoprolol | 681 | $29,244 | $43 |
| Eliquis | 69 | $26,921 | $390 |
| Atorvastatin | 381 | $12,409 | $33 |
| Exforge | 42 | $11,552 | $275 |
| Diltiazem 24hr Cd | 50 | $10,679 | $214 |
| Diovan | 44 | $9,894 | $225 |
| Diltiazem 24hr Er | 123 | $6,958 | $57 |
| Labetalol | 136 | $5,820 | $43 |
| Valsartan | 30 | $5,540 | $185 |
| Potassium Chloride | 132 | $4,953 | $38 |
| Fenofibrate | 24 | $4,800 | $200 |
| Amiodarone | 73 | $4,376 | $60 |
| Zetia | 18 | $3,504 | $195 |
| Digoxin | 66 | $3,475 | $53 |
| Amlodipine Besylate | 373 | $3,313 | $9 |
| Valsartan-Hydrochlorothiazide | 37 | $2,845 | $77 |
| Clopidogrel | 124 | $2,559 | $21 |
| Losartan | 205 | $2,164 | $11 |
| Amlodipine Besylate-Benazepril | 41 | $2,158 | $53 |
| Carvedilol | 204 | $2,084 | $10 |
| Benicar | 11 | $1,803 | $164 |
| Warfarin | 128 | $1,741 | $14 |
| Coumadin | 13 | $1,717 | $132 |
| Flecainide Acetate | 27 | $1,712 | $63 |
| Diltiazem Er | 21 | $1,644 | $78 |
| Torsemide | 44 | $1,617 | $37 |
| Lisinopril | 182 | $1,234 | $7 |
| Digox | 33 | $1,205 | $37 |
| Toprol Xl | 17 | $1,057 | $62 |
| Furosemide | 202 | $1,038 | $5 |
| Simvastatin | 95 | $884 | $9 |
| Taztia Xt | 14 | $820 | $59 |
| Losartan-Hydrochlorothiazide | 45 | $645 | $14 |
| Isosorbide Mononitrate Er | 28 | $637 | $23 |
| Spironolactone | 51 | $631 | $12 |
| Fenofibrate | 16 | $546 | $34 |
| Triamterene-Hydrochlorothiazid | 27 | $362 | $13 |
| Levothyroxine | 25 | $342 | $14 |
| Nitrostat | 20 | $312 | $16 |
| Pantoprazole | 27 | $306 | $11 |
| Felodipine Er | 12 | $283 | $24 |
| Pravastatin | 14 | $273 | $19 |
| Hydrochlorothiazide | 49 | $253 | $5 |
| Lisinopril-Hydrochlorothiazide | 13 | $208 | $16 |
| Ramipril | 12 | $181 | $15 |
| Metoprolol | 21 | $169 | $8 |
| Atenolol | 15 | $116 | $8 |
2013: 50 drugs
| Pradaxa | 158 | $58,056 | $367 |
| Crestor | 185 | $42,724 | $231 |
| Xarelto | 103 | $36,019 | $350 |
| Metoprolol | 600 | $25,079 | $42 |
| Diovan | 63 | $13,223 | $210 |
| Atorvastatin | 312 | $11,789 | $38 |
| Exforge | 22 | $7,305 | $332 |
| Effient | 19 | $6,614 | $348 |
| Diltiazem 24hr Er | 98 | $5,543 | $57 |
| Labetalol | 129 | $5,173 | $40 |
| Amlodipine Besylate | 334 | $4,127 | $12 |
| Fenofibrate | 23 | $4,097 | $178 |
| Valsartan-Hydrochlorothiazide | 27 | $3,815 | $141 |
| Clopidogrel | 94 | $3,147 | $33 |
| Tikosyn | 12 | $3,106 | $259 |
| Coreg Cr | 12 | $2,792 | $233 |
| Losartan | 158 | $2,662 | $17 |
| Carvedilol | 198 | $2,633 | $13 |
| Amiodarone | 76 | $2,446 | $32 |
| Potassium Chloride | 77 | $2,346 | $30 |
| Plavix | 11 | $2,196 | $200 |
| Flecainide Acetate | 29 | $2,152 | $74 |
| Diltiazem Er | 38 | $1,999 | $53 |
| Lisinopril | 266 | $1,901 | $7 |
| Warfarin | 127 | $1,882 | $15 |
| Eplerenone | 13 | $1,850 | $142 |
| Amlodipine Besylate-Benazepril | 30 | $1,604 | $53 |
| Toprol Xl | 14 | $1,451 | $104 |
| Simvastatin | 115 | $1,207 | $10 |
| Torsemide | 26 | $1,024 | $39 |
| Coumadin | 11 | $972 | $88 |
| Diltiazem 24hr Cd | 29 | $882 | $30 |
| Furosemide | 164 | $853 | $5 |
| Losartan-Hydrochlorothiazide | 43 | $757 | $18 |
| Cilostazol | 18 | $729 | $40 |
| Taztia Xt | 11 | $703 | $64 |
| Spironolactone | 35 | $452 | $13 |
| Digox | 49 | $445 | $9 |
| Fenofibrate | 16 | $438 | $27 |
| Digoxin | 26 | $429 | $17 |
| Nitrostat | 30 | $400 | $13 |
| Lisinopril-Hydrochlorothiazide | 40 | $396 | $10 |
| Isosorbide Mononitrate Er | 26 | $364 | $14 |
| Pantoprazole | 20 | $324 | $16 |
| Felodipine Er | 12 | $268 | $22 |
| Omeprazole | 12 | $256 | $21 |
| Hydrochlorothiazide | 43 | $217 | $5 |
| Metoprolol | 25 | $210 | $8 |
| Lovastatin | 11 | $173 | $16 |
| Atenolol | 17 | $120 | $7 |
Money from drug and device companies
$198 in 2025
| 2025 | 2 | 2 | None | $198 |
| 2023 | 2 | 2 | None | $133 |
| 2022 | 2 | 2 | None | $64 |
| 2021 | 1 | 1 | None | $40 |
| 2019 | 1 | 1 | None | $102 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| W. L. Gore & Associates | Gore Cardioform Septal Occluder | $163 | 1 payment
|
| Novartis Pharmaceuticals | Leqvio | $35 | 1 payment
|
See all 2 published payments
| Novartis Pharmaceuticals | Meals · 2025-04-28 | Leqvio | $35 |
| W. L. Gore & Associates | Meals · 2025-02-18 | Gore Cardioform Septal Occluder | $163 |
See earlier years (2023, 2022, 2021, 2019)
2023: $133
| E.R. Squibb & Sons L.L.C. | Camzyos | $109 | 1 payment
|
| Abbott Laboratories | Amplatzer Amulet | $24 | 1 payment
|
2022: $64
| Bardy Diagnostics | Carnation Ambulatory Monitor | $37 | 1 payment
|
| Lantheus Medical Imaging | Definity | $27 | 1 payment
|
2021: $40
| Biosense Webster | Carto 3 | $40 | 1 payment
|
2019: $102
| Medtronic Vascular | 3f | $102 | 1 payment
|
Checkups this office reported
11 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 88.8 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Asked about smokingPatients asked about tobacco, with help to quit if they smoke | 0%That's few of the people this applied to. | 563 |
| Blood pressure under controlPeople with high blood pressure whose reading was in a healthy range | 66%That's more than half. | 498 |
| Coronary Artery Disease (CAD): Beta-Blocker Therapy Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <= 40%)As Medicare defines this measure | 95% | 22 |
| Diabetes poorly controlledPeople with diabetes whose blood sugar stayed very high | 71%That's more than half. Worse on this measure. | 21 |
| Medications listed in the chartVisits where the current medication list was documented | 95%That's most of the people this applied to. | 1,722 |
| Patients can see their records onlinePatients who were given electronic access to their health information | 73%That's more than half. | 804 |
| Prescriptions sent electronicallyPrescriptions sent to the pharmacy by computer instead of paper | 97%That's most of the people this applied to. | 559 |
| Risky medications in older adultsOlder patients given a medication that is risky at their age | 0%That's few of the people this applied to. Better on this measure. | 1,072 |
See the other 3 measures
| Screening for High Blood Pressure and Follow-Up DocumentedAs Medicare defines this measure | 23% | 988 |
| Statin prescribed when it protects the heartPeople at cardiovascular risk who were prescribed a statin | 89%That's most of the people this applied to. | 585 |
| Weight checked, with a follow-up planPatients whose BMI was recorded and followed up if needed | 25%That's less than half. | 1,331 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Agreed to federal review of their records system
- Did a security review of patient data
- Exchanges records both ways with other health systems
- High Priority Practices Guide of the Safety Assurance Factors for EHR Resilience (SAFER) Guides
- Implementation of medication management practice improvements
- Improved the patient portal
- Lets patients read their visit notes
- ONC-ACB Surveillance Attestation
- Reports cases to public health electronically
- Reports immunizations to the state registry
- Reports to a public-health or clinical registry
- Uses standard treatment protocols
- Exempt from query of the prescription drug monitoring program (pdmp)
Professional record
- NPI
- 1679750574
- Licence
- CA A105051California A105051: Current · expires 2027-09-30
- Trained
- Rush Medical College of Rush University, 2002 · 24 years ago
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA GR0068680
- Taxonomy
- Cardiology (207RC0000X)
- Mailing address
- 1370 Chorro St, San Luis Obispo, CA, 93401
- NPI first listed
- 2008-01-23
- NPI last updated
- 2025-10-03
- NPI record certified
- 2025-10-03
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 850 Fair Oaks Ave Ste 100, Arroyo Grande, CA, 93420 · 1911 Johnson Ave, San Luis Obispo, CA, 93401 · 1941 Johnson Ave, San Luis Obispo, CA, 93401 · 1941 Johnson Ave Ste 102, San Luis Obispo, CA, 93401 · 295 Posada Ln Ste A, Templeton, CA, 93465